CD274 and non-small cell lung carcinoma: Over the past decade, the use of immunotherapy strategies involving programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) immune checkpoints has transformed the treatment modalities and therapeutic landscape of NSCLC.